Login
$ENGN
$1.58 +$0.02 (1.28%) Close

Company Executives

$ENGN Management Team

Dr. Richard Glickman

Independent Chairman of the Board

Age 67
Compensation $208.5K USD
Sex Male

Mr. Ronald Cooper

Chief Executive Officer

President and Director

Age 62
Compensation $8.434M USD
Sex Male

Mr. Ryan Daws

Chief Financial Officer and Head - Business Development

Age 51
Compensation -
Sex Male

Ms. Joan Connolly

Chief Technology Officer

Age 56
Compensation -
Sex Female

Dr. Anthony Cheung

Chief Scientific Officer

Age 54
Compensation -
Sex Male

Dr. Alexander Nichols

Chief Strategy and Operations Officer

Age 40
Compensation $970.0K USD
Sex Male

Mr. Lee Giguere

Chief Legal Officer and Corporate Secretary

Age 45
Compensation $3.303M USD
Sex Male

Mr. Matthew Boyd

Chief Regulatory Officer

Age -
Compensation -
Sex Male

Ms. Jill Buck

Chief Development Officer

Age -
Compensation -
Sex Female

Ms. Amy Pott

Chief Global Commercialization Officer

Age 49
Compensation -
Sex Female

Dr. Hussein Sweiti

Chief Medical Officer

Age -
Compensation -
Sex Male
Directors
9
serving now
Independent
8 of 9
stated in the proxy
Average tenure
2.0 years
from year joined
CEO also chairs the board
No
Richard Glickman
Director Age On board Independent Committees Other public boards 2025 pay Source
Philip Astley-Sparke
Not stated 2025
1 year
Independent
audit nominating and corporate governance
None stated $135,956
Ronald H.W. Cooper
Not stated 2024
2 years
Not independent None stated C4 Therapeutics, Inc. Paid as CEO
William Grossman
Not stated 2025
1 year
Independent
research and development · Chair
None stated Not stated
Michael Heffernan
Not stated 2025
1 year
Independent
audit compensation
Biohaven Ltd. $136,274
Gerald Brunk
Not stated 2023
3 years
Independent
compensation · Chair research and development
None stated $121,601
Richard Glickman
Not stated 2023
3 years
Independent
nominating and corporate governance · Chair research and development
Eupraxia Pharmaceuticals Inc. Not stated
Paul Hastings
Not stated 2024
2 years
Independent
compensation nominating and corporate governance
Nkarta, Inc. $106,772
Wouter Joustra
Not stated 2024
2 years
Independent
compensation
NewAmsterdam Pharma N.V., Vor Biopharma, Inc. $101,772
Lota Zoth
Not stated 2023
3 years
Independent
audit · Chair nominating and corporate governance
Inovio Pharmaceuticals, Inc. $117,772

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed May 8, 2026
each of its directors and certain of its executive officers
directors and certain executive officers of enGene
Amount not stated

Indemnification agreements requiring enGene to indemnify these individuals, and in certain cases their affiliates, and to advance expenses for proceedings.

With enGene Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support